Research programme: Thrombosis therapeutics - Transtech Pharma
Alternative Names: TTP 896Latest Information Update: 23 Sep 2010
Price :
$50 *
At a glance
- Originator TransTech Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 23 Sep 2010 Discontinued - Preclinical for Thrombosis in USA (unspecified route)
- 22 Nov 2006 Preclinical trials in Thrombosis in USA (unspecified route)